114 results on '"Guinebretière JM"'
Search Results
2. Abstract P1-14-18: Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without celecoxib for HER2 negative tumor (Remagus 02 trial)
- Author
-
Giacchetti, S, primary, Pierga, J-Y, additional, Delaloge, S, additional, Asselain, B, additional, Brain, E, additional, Guinebretière, JM, additional, Che-Lehman, J, additional, Mathieu, M-C, additional, Sigal, B, additional, and Marty, M, additional
- Published
- 2012
- Full Text
- View/download PDF
3. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis
- Author
-
Geneviève Contesso, Guinebretière Jm, C. Frouge, M Bléry, and Di Paola R
- Subjects
Tumor angiogenesis ,Adult ,Contrast enhancement ,Gadolinium ,chemistry.chemical_element ,Contrast Media ,Breast Neoplasms ,Text mining ,Nuclear magnetic resonance ,Invasive breast carcinoma ,Heterocyclic Compounds ,Organometallic Compounds ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Aged ,medicine.diagnostic_test ,Neovascularization, Pathologic ,business.industry ,Carcinoma, Ductal, Breast ,Resonance ,Magnetic resonance imaging ,General Medicine ,Middle Aged ,equipment and supplies ,Immunohistochemistry ,Magnetic Resonance Imaging ,Carcinoma, Lobular ,chemistry ,business ,human activities - Abstract
The authors determined the relation between tumor angiogenesis in small invasive breast carcinoma and contrast enhancement on magnetic resonance imaging (MRI) after gadolinium injection.Magnetic resonance imaging was performed before surgery in a prospective study of 20 patients who had a small palpable lump. Spin-echo sequences after injection of gadolinium were studied by factor analysis of medical image sequences and were compared with a histologic quantification of tumor angiogenesis after immunocytochemical staining.In nine cases, there was good correlation between the MRI and the histologic plane. In four patients, an early factor was found on MRI. This factor was related to a high concentration of arterioles located in the stroma or, in one patient, to the intratumor repair process.Early enhancement correlated well with the number of vessels determined histologically.
- Published
- 1994
4. MR imaging of clear cell sarcoma (malignant melanoma of the soft parts) : a multicenter correlative MRI-pathology study of 21 cases and literature review
- Author
-
De Beuckeleer, LH, De Schepper, AM, Vandevenne, JE, Bloem, JI, Davies, AM, Oudkerk, M, Hauben, E, van Marck, E, Somville, J, Vanel, D, Steinbach, LS, Guinebretière, JM, Hogendoorn, PCW, Mooi, WJ (Wolter), Verstraete, K, Zaloudek, C, Jones, H, De Beuckeleer, LH, De Schepper, AM, Vandevenne, JE, Bloem, JI, Davies, AM, Oudkerk, M, Hauben, E, van Marck, E, Somville, J, Vanel, D, Steinbach, LS, Guinebretière, JM, Hogendoorn, PCW, Mooi, WJ (Wolter), Verstraete, K, Zaloudek, C, and Jones, H
- Published
- 2000
5. Local recurrence of ductal carcinoma in situ after conservative breast surgery: mammographic features [in French]
- Author
-
El Khoury, M, primary, Mesurolle, B, additional, Cherel, P, additional, Guinebretière, JM, additional, Planter, MM, additional, de Maulmont, C, additional, and Hagay, C, additional
- Published
- 2007
- Full Text
- View/download PDF
6. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.
- Author
-
Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretière JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A, and Cottu PH
- Published
- 2010
- Full Text
- View/download PDF
7. Li-Fraumeni-associated osteosarcomas: The French experience.
- Author
-
Saucier E, Bougeard G, Gomez-Mascard A, Schramm C, Abbas R, Berlanga P, Briandet C, Castex MP, Corradini N, Coze C, Guerrini-Rousseau L, Guinebretière JM, Khneisser P, Lervat C, Mansuy L, Marec-Berard P, Marie-Cardine A, Mascard E, Saumet L, Tabone MD, Winter S, Frebourg T, Gaspar N, and Brugieres L
- Abstract
Purpose: Describe clinical characteristics and outcome of Li-Fraumeni syndrome (LFS)-associated osteosarcomas., Methods: TP53 germline pathogenic/likely pathogenic variant carriers diagnosed with osteosarcoma in France between 1980 and 2019 were identified via the French Li-Fraumeni database at Rouen University Hospital. Sixty-five osteosarcomas in 52 patients with available clinical and histological data were included. The main clinical characteristics were compared with data from National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) for patients of the same age group., Results: Median age at first osteosarcoma diagnosis was 13.7 years (range: 5.9-36.7). Compared to unselected osteosarcomas, LFS-associated osteosarcomas occurred more frequently in patients less than 10 years of age (23% vs. 9%), and when compared with osteosarcomas in patients less than 25 years were characterized by an excess of axial (16% vs. 10%) and jaw sites (15% vs. 3%) and histology with predominant chondroblastic component and periosteal subtypes (17% vs. 1%). Metastases incidence (25%) was as expected in osteosarcomas. After the first osteosarcoma treatment, the rate of good histologic response (62%) and the 5-year progression-free survival (55%, 95% confidence interval [CI]: 42.6-71.1) were as expected in unselected series of osteosarcomas, whereas the 5-year event-free survival was 36.5% [95% CI: 25.3-52.7] due to the high incidence of second malignancies reaching a 10-year cumulative risk of 43.4% [95% CI: 28.5-57.5]., Conclusion: In osteosarcoma, young age at diagnosis, axial and jaw sites, histology with periosteal or chondroblastic subtype, and synchronous multifocal tumors should prompt suspicion of a germline TP53 mutation. Standard treatments are effective, but multiple malignancies impair prognosis. Early recognition of these patients is crucial for tailored therapy and follow-up., (© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
8. Impact of guideline adherence and expert center referral on the early management and outcomes of uterine sarcoma patients: A retrospective analysis from the French NETSARC network.
- Author
-
Richaud C, Jochum F, Journo G, Toussaint A, Laurent M, Fontier Z, Langer A, Malhaire C, Laas E, Féron JG, Lecuru F, Pouget N, Guinebretière JM, El Zein S, Brain E, Watson S, Piperno-Neumann S, Blay JY, Bonvalot S, Bozec L, and Hamy AS
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Guideline Adherence, Referral and Consultation, Sarcoma diagnostic imaging, Sarcoma surgery, Uterine Neoplasms diagnosis, Uterine Neoplasms surgery, Pelvic Neoplasms, Soft Tissue Neoplasms surgery
- Abstract
Objective: Uterine sarcomas are rare tumors with a poor prognosis. Their diagnosis is often incidental, following surgery. Our goal was to examine the early management strategies for uterine sarcomas, and to assess the impact of guideline adherence and expert center referral on both the management approaches and the clinical outcomes in patients with uterine sarcomas., Methods: We retrospectively analyzed medical records from patients with uterine sarcoma referred to the Institut Curie and registered in the database of the French NETSARC network., Results: In total, 100 patients, with a median age of 54 years, were included in the analyses. On MRI scans (n = 36), all patients had at least two signs suggestive of malignancy, and 77.8 % had four or more signs. No preoperative biopsy was performed in 65.6 % of cases. Only 14.1 % of patients underwent initial surgery at an expert center. Surgery performed outside the network was significantly associated with morcellation (32.9 % vs. 0 %; p = 0.036), fewer negative margins (R0 margins 52.4 % vs. 100 %; p = 0.006), and poor adherence to surgical guidelines (28.3 vs. 72.7 %; p = 0.013). Multivariate analysis showed that non-adherence to surgical recommendations was not significantly associated with relapse-free survival (HR = 0.54; 95 % CI [0.21-1.38]), but was an independent predictor of poor overall survival (HR = 0.12; 95 % CI [0.03-0.52]; p = 0.005)., Conclusion: Despite a high frequency of suspicious clinical and radiological signs, a large proportion of women undergoing sarcoma surgery are treated outside of expert networks. We provide guidelines, integrating the clinical context and radiological signs to encourage early referral to reference centers for sarcoma., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
9. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers.
- Author
-
Passeri T, Gutman T, Hamza A, Adle-Biassette H, Girard E, Beaurepere R, Tariq Z, Mariani O, Dahmani A, Bourneix C, Abbritti R, Driouch K, Bohec M, Servant N, Baulande S, Decaudin D, Guichard JP, Calugaru V, Feuvret L, Guinebretière JM, Champion L, Bièche I, Froelich S, Mammar H, and Masliah-Planchon J
- Subjects
- Humans, Prognosis, Precision Medicine, Retrospective Studies, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Biomarkers, Skull Base pathology, Class I Phosphatidylinositol 3-Kinases genetics, Chordoma pathology, Spinal Neoplasms genetics, Skull Base Neoplasms pathology
- Abstract
Objective: Chordomas are rare bone neoplasms characterized by a high recurrence rate and no benefit from any approved medical treatment to date. However, the investigation of molecular alterations in chordomas could be essential to prognosticate, guide clinical decision-making, and identify theranostic biomarkers. The aim of this study was to provide a detailed genomic landscape of a homogeneous series of 64 chordoma samples, revealing driver events, theranostic markers, and outcome-related genomic features., Methods: The authors conducted whole-exome sequencing (WES), targeted next-generation sequencing, and RNA sequencing of 64 skull base and spinal chordoma samples collected between December 2006 and September 2020. Clinical, histological, and radiological data were retrospectively analyzed and correlated to genetic findings., Results: The authors identified homozygous deletions of CDKN2A/2B, PIK3CA mutations, and alterations affecting genes of SWI/SNF chromatin remodeling complexes (PBRM1 and ARID1A) as potential theranostic biomarkers. Using matched germline WES, they observed a higher frequency of a common genetic variant (rs2305089; p.(Gly177Asp)) in TBXT (97.8%, p < 0.001) compared to its distribution in the general population. PIK3CA mutation was identified as an independent biomarker of short progression-free survival (HR 10.68, p = 0.0008). Loss of CDKN2A/2B was more frequently observed in spinal tumors and recurrent tumors., Conclusions: In the current study, the authors identified driver events such as PBRM1 and PIK3CA mutations, TBXT alterations, or homozygous deletions of CDKN2A/2B, which could, for some, be considered potential theranostic markers and could allow for identifying novel therapeutic approaches. With the aim of a future biomolecular prognostication classification, alterations affecting PIK3CA and CDKN2A/2B could be considered as poor prognostic biomarkers.
- Published
- 2023
- Full Text
- View/download PDF
10. [From an optimal management of bone tissue samples to a quality patients' care in 2022 : A new paradigm].
- Author
-
Miquelestorena-Standley E, Tallegas M, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A, Guinebretière JM, Le Loarer F, Galant C, and de Pinieux G
- Subjects
- Bone and Bones, Decalcification Technique methods, Humans, Immunohistochemistry, Bone Neoplasms secondary, Bone Neoplasms therapy
- Abstract
Bone tissue can be involved by primitive or metastatic tumors and requires a specific processing both at the department of pathology and during multidisciplinary meetings. The development of fine-needle percutaneous biopsies and of molecular techniques in bone tumor pathology requires a specific management. Moreover, decalcification of samples is crucial but can be deleterious if not controlled or not appropriate. The aim of this review is to provide recommendations for management and decalcification of bone tumor samples., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. [Notochordal tumors: From notochord to chordoma].
- Author
-
Guinebretière JM and de Pinieux G
- Subjects
- Humans, Notochord pathology, Bone Neoplasms pathology, Chordoma diagnosis, Chordoma pathology, Neoplasms, Germ Cell and Embryonal pathology, Soft Tissue Neoplasms pathology
- Abstract
The group of notochordal tumors consists of the benign notochordal cell tumor and the conventional, dedifferentiated and poorly differentiated chordomas in the fifth edition of the WHO classification of bone and soft tissue tumors. This update covers recent advances in the knowledge of the histogenesis and biology of these tumors and their implications in terms of diagnosis, prognosis assessment and therapeutic management., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. [More than meets the palisade: An unusual tumour of the breast in a male patient].
- Author
-
El Sissy FN, Guinebretière JM, Abed D, Allory Y, and Becette V
- Subjects
- Humans, Male, Breast, Breast Neoplasms
- Published
- 2021
- Full Text
- View/download PDF
13. Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples.
- Author
-
Miquelestorena-Standley E, Jourdan ML, Collin C, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A, Guinebretière JM, Tallegas M, Brulin B, Le Nail LR, Tallet A, Le Loarer F, Massiere J, Galant C, and de Pinieux G
- Subjects
- Edetic Acid pharmacology, Formates pharmacology, Humans, Hydrochloric Acid pharmacology, Immunohistochemistry, Nucleic Acids analysis, Nucleic Acids drug effects, Artifacts, Bone Diseases diagnosis, Decalcification Technique methods, Nucleic Acids agonists
- Abstract
Diagnosis of osteocartilaginous pathologies depends on morphological examination and immunohistochemical and molecular biology analyses. Decalcification is required before tissue processing, but available protocols often lead to altered proteins and nucleic acids, and thus compromise the diagnosis. The objective of this study was to compare the effect of different methods of decalcification on histomolecular analyses required for diagnosis and to recommend an optimal protocol for processing these samples in routine practice. We prospectively submitted 35 tissue samples to different decalcification procedures with hydrochloric acid, formic acid, and EDTA, in short, overnight and long cycles for 1 to >10 cycles. Preservation of protein integrity was examined by immunohistochemistry, and quality of nucleic acids was estimated after extraction (DNA and RNA concentrations, 260/280 ratios, PCR cycle thresholds), analysis of DNA mutations (high-resolution melting) or amplifications (PCR, in situ hybridization), and detection of fusion transcripts (RT-PCR, in situ hybridization). Hydrochloric acid- and long-term formic acid-based decalcification induced false-negative results on immunohistochemistry and molecular analysis. EDTA and short-term formic acid-based decalcification (<5 cycles of 6 h each) did not alter antigenicity and allowed for detection of gene mutations, amplifications or even fusion transcripts. EDTA showed superiority for in situ hybridization techniques. According to these results and our institutional experience, we propose recommendations for decalcification of bone samples, from biopsies to surgical specimens.
- Published
- 2020
- Full Text
- View/download PDF
14. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
- Author
-
Bonneau C, Eliès A, Kieffer Y, Bourachot B, Ladoire S, Pelon F, Hequet D, Guinebretière JM, Blanchet C, Vincent-Salomon A, Rouzier R, and Mechta-Grigoriou F
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Breast Neoplasms immunology, Breast Neoplasms metabolism, Breast Neoplasms therapy, Cancer-Associated Fibroblasts immunology, Carcinoma, Ductal, Breast immunology, Carcinoma, Ductal, Breast metabolism, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast therapy, Carcinoma, Lobular immunology, Carcinoma, Lobular metabolism, Carcinoma, Lobular pathology, Carcinoma, Lobular therapy, Case-Control Studies, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating pathology, Middle Aged, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Prognosis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Survival Rate, Tumor Microenvironment immunology, Breast Neoplasms pathology, Cancer-Associated Fibroblasts pathology
- Abstract
Background: Early luminal breast cancer (BC) represents 70% of newly diagnosed BC cases. Among them, small (under 2 cm) BC without lymph node metastasis (classified as T1N0) have been rarely studied, as their prognosis is generally favorable. Nevertheless, up to 5% of luminal T1N0 BC patients relapse with distant metastases that ultimately prove fatal. The aim of our work was to identify the mechanisms involved in metastatic recurrence in these patients., Methods: Our study addresses the role that autonomous and non-autonomous tumor cell features play with regard to distant recurrence in early luminal BC patients. We created a cohort of T1N0 luminal BC patients (tumors between 0.5-2 cm without lymph node metastasis) with metastatic recurrence ("cases") and corresponding "controls" (without relapse) matched 1:1 on main prognostic factors: age, grade, and proliferation. We deciphered different characteristics of cancer cells and their tumor micro-environment (TME) by deep analyses using immunohistochemistry. We performed in vitro functional assays and highlighted a new mechanism of cooperation between cancer cells and one particular subset of cancer-associated fibroblasts (CAF)., Results: We found that specific TME features are indicative of relapse in early luminal BC. Indeed, quantitative histological analyses reveal that "cases" are characterized by significant accumulation of a particular CAF subset (CAF-S1) and decrease in CD4
+ T lymphocytes, without any other association with immune cells. In multivariate analysis, TME features, in particular CAF-S1 enrichment, remain significantly associated with recurrence, thereby demonstrating their clinical relevance. Finally, by performing functional analyses, we demonstrated that CAF-S1 pro-metastatic activity is mediated by the CDH11/osteoblast cadherin, consistent with bones being a major site of metastases in luminal BC patients., Conclusions: This study shows that distant recurrence in T1N0 BC is strongly associated with the presence of CAF-S1 fibroblasts. Moreover, we identify CDH11 as a key player in CAF-S1-mediated pro-metastatic activity. This is independent of tumor cells and represents a new prognostic factor. These results could assist clinicians in identifying luminal BC patients with high risk of relapse. Targeted therapies against CAF-S1 using anti-FAP antibody or CDH11-targeting compounds might help in preventing relapse for such patients with activated stroma.- Published
- 2020
- Full Text
- View/download PDF
15. Recurrent novel THBS1-ADGRF5 gene fusion in a new tumor subtype "Acral FibroChondroMyxoid Tumors".
- Author
-
Bouvier C, Le Loarer F, Macagno N, Aubert S, Audard V, Geneste D, Gomez-Brouchet A, Guinebretière JM, Larousserie F, Pissaloux D, Marie B, Tirode F, Baud J, and De Pinieux G
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Oncogene Fusion genetics, Fingers pathology, Neoplasms, Connective Tissue genetics, Receptors, G-Protein-Coupled genetics, Soft Tissue Neoplasms genetics, Thrombospondin 1 genetics, Toes pathology
- Abstract
Acral soft tissue tumors are common neoplasms, a subset of which pose a diagnostic challenge. We report 10 cases of a previously unrecognized acral benign soft tissue tumor. These tumors arose on the fingers and toes and involved bone in half of cases. Histologically, the tumors were lobulated and displayed an abundant stroma made of variable fibrous, chondroid and myxoid material reminiscent of cartilaginous or myoepithelial differentiation. Tumor cells harbored small round to reniform nuclei with clear chromatin and inconspicuous nucleoli along with scant eosinophilic cytoplasm. The cells were mostly arranged haphazardly in the stroma but also in small clusters. No mitotic activity was detected. No specific feature was identified in recurrent cases. By immunohistochemistry, the cells consistently stained for CD34 (10/10), ERG (9/10), and SOX9 (7/10). Whole RNA sequencing identified a previously undescribed recurrent in frame THBS1-ADGRF5 gene fusion in all cases. The transcript was confirmed by RT-PCR and was not found in the control group of mimickers including soft tissue chondromas. We propose the name of Acral FibroChondroMyxoid Tumors for this new entity.
- Published
- 2020
- Full Text
- View/download PDF
16. [Clear cell sarcoma or gastrointestinal neuroectodermal tumor (GNET) of the tongue? Case report and review of the literature of an extremely rare tumor localization].
- Author
-
Breton S, Dubois M, Geay JF, Gillebert Q, Tordjman M, Guinebretière JM, and Denoux Y
- Subjects
- Adult, Diagnosis, Differential, Female, Gastrointestinal Neoplasms pathology, Humans, Neuroectodermal Tumors pathology, Sarcoma, Clear Cell pathology, Tongue Neoplasms pathology
- Abstract
Clear cells sarcomas (CCS) are exceptionally rare in the tongue, with, to our knowledge, only three previous reports in anglo-saxon literature. Through our case, we will discuss the differential diagnosis of clear cells tumors of the tongue and bring this tumour closer to the newly described entity of the gastrointestinal tract named "clear cells sarcoma-like gastrointestinal (SCCLGI)", recently renamed "gastrointestinal neuroectodermal tumour (GNET)". SCCLGI/GNET share morphological and molecular characteristics with SCC but had until then been observed only in the digestive tract. Our case could be a lingual localization of a SCCLGI/GNET. SCC and SCCLGI/GNET characteristic molecular profil involves EWSR1-ATF1 [t(12; 22) (q13; q12)] and EWSR1-CREB1 [t(2; 22) (q34; q12)] fusion genes, but it is not specific of these tumours., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
17. Transcriptomic definition of molecular subgroups of small round cell sarcomas.
- Author
-
Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer F, Bouvet M, Galmiche-Rolland L, Larousserie F, Longchampt E, Ranchere-Vince D, Pierron G, Delattre O, and Tirode F
- Subjects
- Biomarkers, Tumor genetics, DNA-Binding Proteins genetics, Gene Fusion genetics, Humans, Muscle Proteins genetics, Repressor Proteins genetics, Transcription Factors genetics, Bone Neoplasms genetics, Oncogene Proteins, Fusion genetics, Sarcoma, Small Cell genetics, Transcriptome genetics
- Abstract
Sarcoma represents a highly heterogeneous group of tumours. We report here the first unbiased and systematic search for gene fusions combined with unsupervised expression analysis of a series of 184 small round cell sarcomas. Fusion genes were detected in 59% of samples, with half of them being observed recurrently. We identified biologically homogeneous groups of tumours such as the CIC-fused (to DUX4, FOXO4 or NUTM1) and BCOR-rearranged (BCOR-CCNB3, BCOR-MAML3, ZC3H7B-BCOR, and BCOR internal duplication) tumour groups. VGLL2-fused tumours represented a more biologically and pathologically heterogeneous group. This study also refined the characteristics of some entities such as EWSR1-PATZ1 spindle cell sarcoma or FUS-NFATC2 bone tumours that are different from EWSR1-NFATC2 tumours and transcriptionally resemble CIC-fused tumour entities. We also describe a completely novel group of epithelioid and spindle-cell rhabdomyosarcomas characterized by EWSR1- or FUS-TFCP2 fusions. Finally, expression data identified some potentially new therapeutic targets or pathways. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd., (Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
18. [Histological diagnosis of bone tumors: Guidelines of the French committee of bone pathologists reference network on bone tumors (RESOS)].
- Author
-
Galant C, Bouvier C, Larousserie F, Aubert S, Audard V, Brouchet A, Marie B, Guinebretière JM, and de Pinieux du Bouexic G
- Subjects
- Bone Neoplasms diagnosis, Contraindications, Procedure, France, Humans, Image-Guided Biopsy instrumentation, Needles standards, Pathologists, Specimen Handling methods, Specimen Handling standards, Bone Neoplasms pathology, Bone and Bones pathology, Image-Guided Biopsy standards
- Abstract
The management of patients having a bone lesion requires in many cases the realization of a histological sample in order to obtain a diagnosis. However, with the technological evolution, CT-guided biopsies are performed more frequently, often in outpatient clinics. Interpretation of these biopsies constitutes new challenges for the pathologists within the wide spectrum of bone entities. The purpose of the document is to propose guidelines based on the experience of the French committee of bone pathologists of the reference network on bone tumors (RESOS) regarding the indications and limitations of the diagnosis on restricted material., (Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
19. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques].
- Author
-
Macagno N, Caselles K, Aubert S, Audard V, Gomez-Brouchet A, Galant C, Guinebretière JM, Karanian M, Larousserie F, Marie B, de Pinieux G, and Bouvier C
- Subjects
- Biomarkers, Tumor analysis, Bone Cysts, Aneurysmal chemistry, Bone Cysts, Aneurysmal diagnosis, Bone Cysts, Aneurysmal pathology, Bone Diseases diagnosis, Bone Diseases metabolism, Bone Neoplasms chemistry, Bone Neoplasms diagnosis, Bone Neoplasms secondary, Chondroblastoma chemistry, Chondroblastoma diagnosis, Chondroblastoma pathology, Diagnosis, Differential, Fibroma, Ossifying chemistry, Fibroma, Ossifying diagnosis, Fibroma, Ossifying pathology, Genetic Markers, Giant Cell Tumor of Bone chemistry, Giant Cell Tumor of Bone diagnosis, Giant Cell Tumor of Bone pathology, Humans, Immunohistochemistry methods, Molecular Diagnostic Techniques, Sarcoma chemistry, Sarcoma diagnosis, Sarcoma pathology, Bone Diseases pathology, Bone Neoplasms pathology, Giant Cells pathology
- Abstract
The infiltration by numerous osteoclastic giant cells is a frequent finding in bone tumors and pseudo-tumors. Pathologists must integrate clinical and radiological data to achieve a correct diagnosis in bone pathology. Benign giant-cell rich lesions of bone encompass giant cell tumor of bone, aneurysmal bone cyst, chondroblastoma, brown tumor and fibrous cortical defect/non-ossifying fibroma. Amongst malignant neoplasms, variants of conventional osteosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma and bone metastasis must be discussed. Recently, new diagnostic markers, antibodies for immuno-histochemistry and genetic markers, have been developed and are helpful to diagnose such lesions., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
20. COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2 -negative Breast Cancer Patients.
- Author
-
DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, and Bièche I
- Subjects
- Adult, Breast Neoplasms genetics, Breast Neoplasms metabolism, Cyclooxygenase 2 Inhibitors therapeutic use, Female, Humans, Middle Aged, Multivariate Analysis, Neoadjuvant Therapy, Predictive Value of Tests, Prognosis, Prospective Studies, Receptor, ErbB-2 metabolism, Remission Induction, Treatment Outcome, Breast Neoplasms drug therapy, Celecoxib therapeutic use, Cyclooxygenase 2 genetics, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic
- Abstract
Background: The prognostic and predictive role of cyclo-oxygenase-2 (COX2) in breast cancer is still debated, and in particular, its role as a target of COX2 inhibitor (celecoxib) in neoadjuvant setting., Materials and Methods: We analyzed a series of 156 breast cancer samples from patients of the COX2 inhibitor-treated arm included in the REMAGUS-02 randomized phase II trial. COX2 gene expression was assessed by reverse transcription and quantitative polymerase chain reaction using ribonucleic acid from frozen biopsies. Pathological complete response (pCR) was the surrogate end-point., Results: Significantly higher rates of grade 3, and estrogen and progesterone receptor negativity were observed in tumors with the highest expression of COX2. pCR rates were significantly higher in COX2-overexpressing tumors in patients receiving celecoxib. The test for interaction between COX2 gene expression and the celecoxib effect was statistically significant (p<0.01), but was not retained in the multivariate analysis., Conclusion: COX2 overexpression is predictive of pCR in patients with celecoxib-treated tumors. The efficacy of celecoxib in breast cancer might be improved by quantification of COX2 gene expression., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
21. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
- Author
-
Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, and Rouzier R
- Subjects
- Breast Neoplasms drug therapy, Chemotherapy, Adjuvant, Female, France, Health Planning Guidelines, Humans, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Physicians, Prospective Studies, Treatment Outcome, Breast Neoplasms diagnosis, Breast Neoplasms pathology
- Abstract
Purpose: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results., Methods: Consecutive patients with invasive early-stage breast cancer were enrolled in a prospective, observational, multicenter study carried out in 8 hospitals in France. The Prosigna test was carried out on surgical specimens using the nCounter® Analysis System located at the Institut Curie. Both before and after receiving the Prosigna test results, physicians completed treatment confidence questionnaires and patients completed questionnaires concerning their state of anxiety, the difficulties felt in face of the therapy and quality of life. Information was also collected at 6 months regarding the physicians' opinion on the test results and the patients' degree of anxiety, difficulties with therapy and quality of life., Results: Between March 2015 and January 2016, 8 study centers in France consecutively enrolled 210 postmenopausal women with estrogen receptor (ER) positive, human epidermal growth hormone-2 (HER-2) negative, and node negative tumors, either stage 1 or stage 2. Intrinsic tumor subtypes as assessed by the Prosigna test were 114 (58.2%) Luminal A, 79 (40.3%) Luminal B, 1 (0.5%) HER-2 enriched (HER-2E), and 2 (1.0%) basal-like. Before receiving the Prosigna test results, physicians categorized tumor subtypes based on immunohistochemistry (IHC) as Luminal A in 126 (64%) patients and Luminal B in 70 (36%) patients, an overall discordance rate of 25%. The availability of Prosigna assay results was significantly associated with the likelihood of change in treatment recommendations, with 34 patients (18%) having their treatment plan changed from Adjuvant Chemotherapy to No Adjuvant Chemotherapy or vice versa (p<0.001, Fisher's exact test). Prosigna test results also decreased patients' anxiety about the chosen adjuvant therapy, and improved emotional well-being and measures of personal perceptions of uncertainty., Conclusions: The results of this prospective decision impact study are consistent with 2 previous, identically designed studies carried out in Spain and Germany. The availability of Prosigna test results increased the confidence of treating physicians in their adjuvant treatment decisions, and led to an 18% change in chemotherapy treatment plan (from Adjuvant Chemotherapy to No Adjuvant Chemotherapy or vice versa). Prosigna testing decreased anxiety and improved measures of health-related quality of life in patients facing adjuvant therapy. The 25% discordance between Prosigna test and IHC subtyping underlines the importance of molecular testing for optimal systemic therapy indications in early breast cancer.
- Published
- 2017
- Full Text
- View/download PDF
22. [Genomic tests in early breast cancer management: Real-life experience].
- Author
-
Yazigi A, Callens C, Jaillot A, Lerebours F, Guinebretière JM, Rouzier R, and Héquet D
- Subjects
- Breast Neoplasms pathology, Chemotherapy, Adjuvant, Female, Genetic Testing, Humans, Middle Aged, Neoplasm Recurrence, Local, Risk, Breast Neoplasms drug therapy, Breast Neoplasms genetics
- Published
- 2017
- Full Text
- View/download PDF
23. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
- Author
-
Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, and Pierga JY
- Subjects
- Adult, Aged, Celecoxib administration & dosage, Chemotherapy, Adjuvant, Cyclophosphamide administration & dosage, Epirubicin administration & dosage, Female, Humans, Middle Aged, Receptor, ErbB-2 metabolism, Trastuzumab administration & dosage, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
Background: The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate. We report here the long-term follow-up results for disease-free survival (DFS) and overall survival (OS)., Patients and Methods: From 2004 to 2007, 340 stage II-III BC patients were randomly assigned to receive neoadjuvant EC-T (four cycles of epirubicin-cyclophosphamide followed by four cycles of docetaxel) +/- celecoxib in HER2-negative cases (n = 220) and ± trastuzumab in HER2-positive cases (n = 120). From September 2005, all patients with HER2-positive BC received adjuvant T (n = 106)., Results: Median follow-up was nearly 8 years (94.4 months, 20-127 m). In the HER2-negative subgroup, addition of celecoxib was not associated with a DFS benefit. Favourable factors were smaller tumour size, expression of progesterone receptor status (PgR) and pCR. In the HER2-positive population, neoadjuvant trastuzumab was not associated with a DFS benefit. Axillary pCR was the only prognostic factor associated with DFS in this group [HR = 0.44, 95% CI = 0.2-0.97], p = 0.035]. To note, DFS and OS were significantly higher in the HER2-positive than in HER2-negative BC patients (HR = 0.58 [0.36-0.92], p = 0.021)., Conclusion: Celecoxib combined with NAC provided neither pCR nor survival benefit in patients with HER2-negative BC. Absence of PgR is a major prognostic factor. Neoadjuvant trastuzumab increased pCR rates without translation into a DFS or OS benefit compared with adjuvant trastuzumab only. Axillary pCR could be a more relevant surrogate of survival than in the breast in HER2-positive population. A retrospective comparison shows that patients with HER2-positive tumours have a better outcome than HER2-negative BC patients showing the impact of trastuzumab on the natural history of BC., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
24. Tumoral heterogeneity of breast cancer.
- Author
-
Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, and Rouzier R
- Subjects
- Biomarkers, Tumor analysis, Breast Neoplasms genetics, Breast Neoplasms therapy, Female, Genetic Heterogeneity, Humans, Molecular Targeted Therapy methods, Molecular Targeted Therapy trends, Breast Neoplasms classification, Breast Neoplasms pathology
- Abstract
The objective of this literature review is to describe the types of tumor heterogeneity in breast cancer and their clinical implication. Two kinds of tumor heterogeneity are described: intertumor heterogeneity and intra-tumor heterogeneity. In breast cancer, inter-tumor heterogeneity was best characterized in the 2000s thanks to high throughput analyses. These analyzes resulted in a molecular classification of breast cancers distinguishing four subtypes: Luminal A, Luminal B, HER 2+ and basal like. This variability may be observed between the primary tumor and metastases, namely the temporal intratumor heterogeneity. The average discrepancy for the progesterone receptor, estrogen, and between HER2 status appears to be 33%, 20% and 8%, respectively. It is then interesting to study the heterogeneity within the primary tumor: this spatial intra-tumor heterogeneity is poorly known. Physiopathology of intra-tumor heterogeneity light be deciphered by studies on cancer stem cells and clonal evolution model. In addition, the tumor microenvironment seems to actively contribute to this heterogeneity. The major interest to study this heterogeneity is the clinical implication that could result. While precision medicine is emerging, it is important to capture the heterogeneity of each specific tumor type. These new biological knowledge will allow us to anticipate such heterogeneity and individualize the management of breast cancer.
- Published
- 2016
- Full Text
- View/download PDF
25. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
- Author
-
Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, and de Cremoux P
- Subjects
- Adult, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Cycle Proteins genetics, Clinical Trials, Phase II as Topic, Cyclophosphamide therapeutic use, Docetaxel, Epirubicin therapeutic use, Female, Humans, Middle Aged, Multicenter Studies as Topic, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Survivin, Taxoids therapeutic use, Trans-Activators genetics, Treatment Outcome, Trefoil Factor-1, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Breast Neoplasms drug therapy, Inhibitor of Apoptosis Proteins genetics
- Abstract
Purpose: Neoadjuvant systemic therapy (NAC) is currently used in the treatment of stage II/III breast cancer. Pathological complete response as a surrogate endpoint for clinical outcomes is not completely validated for all subgroups of breast cancers. Therefore, there is a need for reliable predictive tests of the most effective treatment., Methods: We used a combination of predictive clinical, pathological, and gene expression-based markers of response to NAC in a prospective phase II multicentre randomized clinical trial in breast cancer patients, with a long follow-up (8 years). This study concerned the subpopulation of 188 patients with similar levels of pathological response rates to sequential epirubicin/cyclophosphamide and docetaxel to determine predictive marker of pCR and DFS. We used a set of 45 genes selected from high throughput analysis and a standardized RT-qPCR. We analyzed the predictive markers of pathological complete response (pCR) and DFS in the overall population and DFS the subpopulation of 159 patients with no pCR., Results: In the overall population, combining both clinical and genomic variables, large tumor size, low TFF1, and MYBL2 overexpression were significantly associated with pCR. T4 Stage, lymphovascular invasion, negative PR status, histological type, and high values of CCNB1 were associated with DFS. In the no pCR population, only lymphovascular invasion and high values of BIRC5 were associated with DFS., Conclusions: We confirm the importance of ER-related and proliferation genes in the prediction of pCR in NAC-treated breast cancer patients. Furthermore, we identified BIRC5 (survivin) as a main pejorative prognostic factor in patients with breast cancers with no pCR. These results also open perspective for predictive markers of new targeted therapies.
- Published
- 2016
- Full Text
- View/download PDF
26. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
- Author
-
Wesseling J, Tinterri C, Sapino A, Zanconati F, Lutke-Holzik M, Nguyen B, Deck KB, Querzoli P, Perin T, Giardina C, Seitz G, Guinebretière JM, Barone J, Dekker L, de Snoo F, Stork-Sloots L, Roepman P, Watanabe T, and Cusumano P
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Female, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry methods, Middle Aged, Receptors, Progesterone metabolism, Reproducibility of Results, Young Adult, Breast Neoplasms metabolism, Breast Neoplasms pathology, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism
- Abstract
To compare results from messenger RNA (mRNA)-based TargetPrint testing with those from immunohistochemistry (IHC) and in situ hybridization (ISH) conducted according to local standard procedures at hospitals worldwide. Tumor samples were prospectively obtained from 806 patients at 22 hospitals. The mRNA level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was assessed by TargetPrint quantitative gene expression readouts. IHC/ISH assessments were performed according to local standards at the participating hospitals. TargetPrint readout showed a high concordance with IHC/ISH of 95 % (kappa 0.81) for ER, 81 % (kappa 0.56) for PR, and 94 % (kappa 0.76) for HER2. The positive/negative agreement between TargetPrint and IHC for ER, PR, and HER2 was 96 %/87 %, 84 %/74 %, and 74 %/98 %, respectively. The concordance rate in IHC/ISH results between hospitals varied: 88-100 % for ER (kappa 0.50-1.00); 50-100 % for PR (kappa 0.20-1.00); and 90-100 % for HER2 (kappa 0.59-1.00). mRNA readout of ER, PR, and HER2 status by TargetPrint was largely comparable to local IHC/ISH analysis. However, there was substantial discordance in IHC/ISH results between different hospitals. When results are discordant, the use of TargetPrint would improve the reliability of hormone receptor and HER2 results by prompting retesting in a reference laboratory.
- Published
- 2016
- Full Text
- View/download PDF
27. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
- Author
-
Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, and Brugières L
- Subjects
- Adolescent, Adult, Bone Neoplasms pathology, Case-Control Studies, Child, Child, Preschool, Cisplatin administration & dosage, Combined Modality Therapy, Diphosphonates administration & dosage, Doxorubicin administration & dosage, Female, Follow-Up Studies, Humans, Ifosfamide administration & dosage, Imidazoles administration & dosage, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Osteosarcoma secondary, Prognosis, Survival Rate, Young Adult, Zoledronic Acid, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Osteosarcoma drug therapy, Osteosarcoma surgery
- Abstract
Background: Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma., Methods: In this randomised, multicentre, open-label, phase 3 trial (OS2006), patients aged between 5 years and 50 years with newly diagnosed high-grade osteosarcoma were randomly assigned to receive standard chemotherapy with or without ten zoledronate intravenous infusions (four preoperative and six postoperative). Adults older than 25 years received 4 mg zoledronate per infusion, patients aged 18-25 years received 0·05 mg/kg for the first two infusions and 4 mg for the remaining eight infusions, and younger patients received 0·05 mg/kg per infusion. Chemotherapy comprised high-dose methotrexate based chemotherapy in patients younger than 18 years, and doxorubicin, ifosfamide, and cisplatin in adults older than 25 years; patients aged 18-25 years were treated with either regime at the discretion of the treating centre. Balanced randomisation between the two groups was done centrally with online randomisation software, based on a minimisation algorithm taking into account centre, age, combined with chemotherapy regimen, and risk group (resectable primary and no metastasis vs other). Patients and investigators were not masked to treatment assignment, but the endpoint adjudication committee members who reviewed suspected early progressions were masked to group allocation. The primary endpoint was event-free survival, estimated from the randomisation to the time of first failure (local or distant relapse, progression, death) or to the last follow-up visit for the patients in first complete remission, analysed on a modified intention-to-treat population, which excluded patients found not to have a malignant tumour after central review. Three interim analyses were planned. This trial is registered with ClinicalTrials.gov, number NCT00470223., Findings: Between April 23, 2007, and March 11, 2014, 318 patients, median age 15·5 years (range 5·8-50·9), were enrolled from 40 French centres; of whom 158 were assigned to the control group (chemotherapy alone) and 160 to the zoledronate group, including 55 (17%) patients with definite metastases. The trial was stopped for futility after the second interim analysis. With a median follow-up of 3·9 years (IQR 2·7-5·1), 125 events occurred (55 in the control group and 70 in the with zoledronate group). Event-free survival at 3 years for all 315 randomly assigned patients was 60·3% (95% CI 64·5-65·9); 3-year event-free survival was 63·4% (55·2-70·9) for the control group and 57·1% (48·8-65·0) for the zoledronate group. The risk of failure was not reduced and was even marginally higher in the zoledronate group than in the control group (hazard ratio [HR] 1·36 [95% CI 0·95-1·96]; p=0·094). No major increase in severe toxic effects of grade 3 or higher associated with zoledronate, barring expected hypocalcaemia (45 [29%] of 153 participants in the zoledronate group vs ten [6%] of 155 participants in the control group; p<0·0001) and hypophosphataemia (61 [40%] of 151 in the zoledronate group vs 26 [17%] of 156 in the control group; p<0·0001). No significant difference in orthopaedic complications was noted between the two groups (27 in the control group and 29 in the zoledronate group). Two treatment-related deaths were reported (one from cardiomyopathy in the control group and one from multiorgan failure in the zoledronate group before the first zoledronate infusion)., Interpretation: From the results observed in this study, we do not recommend zoledronate in osteosarcoma patients. Further biological studies are required to understand the discordance between the results of OS2006 trial and preclinical data., Funding: French National Cancer Institute (INCa), Novartis, Chugai, Ligue Nationale contre le Cancer, Fédération Enfants et Santé, Société Française des Cancers et Leucémies de l'Enfant., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
28. [Shall all lobular intraepithelial neoplasia diagnosed on image-guided biopsy require a surgical management?].
- Author
-
Fischer-Hunsinger M, Guinebretière JM, Lasry S, Langer A, Berment H, Nekka I, Nodiot P, and Cherel P
- Subjects
- Adult, Aged, Aged, 80 and over, Breast diagnostic imaging, Breast pathology, Breast surgery, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Calcinosis diagnostic imaging, Calcinosis pathology, Calcinosis surgery, Carcinoma in Situ diagnostic imaging, Carcinoma in Situ pathology, Carcinoma, Lobular diagnostic imaging, Carcinoma, Lobular pathology, Female, Humans, Hyperplasia diagnostic imaging, Hyperplasia pathology, Hyperplasia surgery, Image-Guided Biopsy, Middle Aged, Precancerous Conditions diagnostic imaging, Precancerous Conditions pathology, Retrospective Studies, Watchful Waiting, Breast Neoplasms surgery, Carcinoma in Situ surgery, Carcinoma, Lobular surgery, Precancerous Conditions surgery, Unnecessary Procedures
- Abstract
Objective: Lobular intraepithelial neoplasia (LIN) diagnosed on image-guided biopsy may be associated with an undiagnosed cancer. This is called under-diagnosis. The consequence is that management of these lesions is often surgical. But many surgeries finally are unnecessary. The aim of our study was to define criteria to avoid unnecessary surgery., Materials and Methods: This is a single-center, retrospective after a database collected prospectively study. Fourteen thousand biopsies were analyzed, including 456 diagnosed NLI. Under-diagnosis rates were analyzed according to many criteria. The average duration of following was 45 months., Results: For atypical lobular hyperplasia (ALH), we obtained 7.6% under-diagnosis and combining several criteria, we got a low risk of cancer (2%). For LCIS, this rate was 23% and any low-risk group could be identified., Conclusion: ALH with calcifications≤20 mm, without any atypical lesion associated, histologically focal and whose removal is representative may be safely observed. For other LIN, surgery remains indicated., (Copyright © 2016 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
29. Mechanical Signals Inhibit Growth of a Grafted Tumor In Vivo: Proof of Concept.
- Author
-
Brossel R, Yahi A, David S, Moreno Velasquez L, and Guinebretière JM
- Subjects
- Animals, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Magnetic Fields, Mice, Mice, Inbred BALB C, Mice, Nude, Nanoparticles administration & dosage, Physiological Phenomena physiology, Stress, Mechanical, Cell Proliferation physiology, Neoplasms pathology
- Abstract
In the past ten years, many studies have shown that malignant tissue has been "normalized" in vitro using mechanical signals. We apply the principles of physical oncology (or mechanobiology) in vivo to show the effect of a "constraint field" on tumor growth. The human breast cancer cell line, MDA MB 231, admixed with ferric nanoparticles was grafted subcutaneously in Nude mice. The magnetizable particles rapidly surrounded the growing tumor. Two permanent magnets located on either side of the tumor created a gradient of magnetic field. Magnetic energy is transformed into mechanical energy by the particles acting as "bioactuators", applying a constraint field and, by consequence, biomechanical stress to the tumor. This biomechanical treatment was applied 2 hours/day during 21 days, from Day 18 to Day 39 following tumor implantation. The study lasted 74 days. Palpable tumor was measured two times a week. There was a significant in vivo difference between the median volume of treated tumors and untreated controls in the mice measured up to D 74 (D 59 + population): (529 [346; 966] mm3 vs 1334 [256; 2106] mm3; p = 0.015), treated mice having smaller tumors. The difference was not statistically significant in the group of mice measured at least to D 59 (D 59 population). On ex vivo examination, the surface of the tumor mass, measured on histologic sections, was less in the treated group, G1, than in the control groups: G2 (nanoparticles, no magnetic field), G3 (magnetic field, no nanoparticles), G4 (no nanoparticles, no magnetic field) in the D 59 population (Median left surface was significantly lower in G1 (5.6 [3.0; 42.4] mm2, p = 0.005) than in G2 (20.8 [4.9; 34.3]), G3 (16.5 [13.2; 23.2]) and G4 (14.8 [1.8; 55.5]); Median right surface was significantly lower in G1 (4.7 [1.9; 29.2] mm2, p = 0.015) than in G2 (25.0 [5.2; 55.0]), G3 (18.0 [14.6; 35.2]) and G4 (12.5 [1.5; 51.8]). There was no statistically significant difference in the day 59+ population. This is the first demonstration of the effect of stress on tumor growth in vivo suggesting that biomechanical intervention may have a high translational potential as a therapy in locally advanced tumors like pancreatic cancer or primary hepatic carcinoma for which no effective therapy is currently available.
- Published
- 2016
- Full Text
- View/download PDF
30. Pathological Characteristics of Both Tumors in Bifocal and Bicentric Breast Cancer.
- Author
-
Mosbah R, Rouzier R, Guinebretière JM, Falcou MC, Stevens D, and Héquet D
- Subjects
- Breast Neoplasms surgery, Female, Humans, Ki-67 Antigen metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Breast Neoplasms pathology
- Abstract
Aim: The objective of the present study was to describe the biological characteristics of each lesion in patients with bifocal/bicentric (BF/BC) breast cancer., Patients and Methods: We retrospectively reviewed the charts of 205 patients diagnosed with BF/BC cancer. The degree of concordance between the two lesions was assessed using Pearson product-moment correlation coefficients., Results: A total of 205 patients were included. Both tumors displayed the same histological type in 182 patients (89%). The same grade was found for both tumors in 178 of the cases (96.7% and 100% for grade 3 lesions). Immunohistochemical concordance between the two tumors was excellent, with correlation coefficients of 0.98, 0.96 and 0.99 for estrogen receptors (ER), progesterone receptors (PR) and Ki67, respectively. Human Epidermal growth factor Receptor 2 (HER2) status was available for both tumors in 177 cases (86%), with a perfect concordance. We did not find any differences in molecular sub-type between tumor foci., Conclusion: Immunohistochemistry should be performed only on the main tumor in cases of BF/BC cancer., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
31. Comments on Carter et al's "activating GNAS mutations in parosteal osteosarcoma".
- Author
-
Tabareau-Delalande F, Collin C, Larousserie F, Bouvier C, Gomez-Brouchet A, Aubert S, Guinebretière JM, Decouvelaere AV, de Muret A, Pagès JC, and de Pinieux G
- Subjects
- Female, Humans, Male, Biomarkers, Tumor analysis, Bone Neoplasms genetics, GTP-Binding Protein alpha Subunits, Gs genetics, Mutation, Osteosarcoma genetics
- Published
- 2015
- Full Text
- View/download PDF
32. SWI/SNF chromatin remodeling and human malignancies.
- Author
-
Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F, and Delattre O
- Subjects
- Animals, Humans, Mutation, Chromatin Assembly and Disassembly physiology, Chromosomal Proteins, Non-Histone genetics, Chromosomal Proteins, Non-Histone metabolism, Neoplasms genetics, Neoplasms metabolism, Transcription Factors genetics, Transcription Factors metabolism
- Abstract
The SWI/SNF complexes, initially identified in yeast 20 years ago, are a family of multi-subunit complexes that use the energy of adenosine triphosphate (ATP) hydrolysis to remodel nucleosomes. Chromatin remodeling processes mediated by the SWI/SNF complexes are critical to the modulation of gene expression across a variety of cellular processes, including stemness, differentiation, and proliferation. The first evidence of the involvement of these complexes in carcinogenesis was provided by the identification of biallelic, truncating mutations of the SMARCB1 gene in malignant rhabdoid tumors, a highly aggressive childhood cancer. Subsequently, genome-wide sequencing technologies have identified mutations in genes encoding different subunits of the SWI/SNF complexes in a large number of tumors. SWI/SNF mutations, and the subsequent abnormal function of SWI/SNF complexes, are among the most frequent gene alterations in cancer. The mechanisms by which perturbation of the SWI/SNF complexes promote oncogenesis are not fully elucidated; however, alterations of SWI/SNF genes obviously play a major part in cancer development, progression, and/or resistance to therapy.
- Published
- 2015
- Full Text
- View/download PDF
33. [Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey].
- Author
-
Fekih M, Petit T, Zarca D, Guinebretière JM, André F, Pierga JY, Namer M, Gligorov J, and Delaloge S
- Subjects
- Biomarkers, Tumor analysis, Breast Neoplasms pathology, Female, France, General Surgery statistics & numerical data, Health Care Surveys statistics & numerical data, Humans, Medical Oncology statistics & numerical data, Middle Aged, Neoplasm Recurrence, Local, Practice Guidelines as Topic, Radiation Oncology statistics & numerical data, Antineoplastic Agents therapeutic use, Breast Neoplasms chemistry, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant standards, Decision Making, Guideline Adherence statistics & numerical data
- Abstract
Adjuvant chemotherapy for localised breast cancer aims at reducing the risk of relapse and at increasing overall survival. Decision criteria include tumour burden and biological profile. It appears currently difficult to evaluate the benefit/risk ratio in certain borderline cases, which are more and more frequent. We have evaluated through an anonymous web survey conducted as part of the 2013 Annual Saint-Paul-de-Vence breast conference, the chemotherapy decisions, use of guidelines and level of certainty with decisions in this type of situation through four clinical cases. The survey was proposed to 1,190 French physicians who are directly in charge of breast cancer care, whatever their specialty. Three hundred and fifty-three of them replied, of whom 67 % were oncologists and 15 % surgeons. A significantly heterogeneous decision was observed for two out of four cases, in which 52 and 69 % of the physicians opted for adjuvant chemotherapy, versus 48 and 21 % for abstention respectively. Eighty seven percent of responding physicians used guidelines to guide their decision. These guidelines were regional for 63 %, national for 36 %, local in 21 % and international in 16 % of the cases. The level of certainty varied with clinical cases but not with the physician's specialty, nor type of decision.
- Published
- 2014
- Full Text
- View/download PDF
34. How to read a pathology report of a bone tumor.
- Author
-
Guinebretière JM, Kreshak J, Suciu V, Maulmont CD, Mascard E, Missenard G, Larousserie F, and Vanel D
- Subjects
- France, Humans, Biomarkers, Tumor metabolism, Biopsy methods, Bone Neoplasms metabolism, Bone Neoplasms pathology, Documentation methods, Health Records, Personal
- Abstract
The interpretation of a biopsy specimen involving bone is one of the most challenging feats for a pathologist, as it is often difficult to distinguish between benign or reactive lesions and malignant tumors on microscopic analysis. Therefore, correlation with the clinical data and imaging is essential and sometimes it is only the evolution of certain characteristics over time or information garnered from molecular analysis that can provide an accurate diagnosis. The pathology report is critical in that it will define subsequent patient management; its wording must precisely reflect those elements that are known with certainty and those that are diagnostic hypotheses. It must be systematic, thorough, and complete and should not be limited to a simple conclusion. The pathologist must first ensure the completeness and correct transcription of the information provided with the specimen, then describe and analyze the histology as well as the quality and representative nature of the sample (as they relate to the radiographic findings and preliminary/final diagnoses), and finally, compare what is seen under the microscope with the assessment made by the radiologist and/or surgeon. This analysis helps to identify difficult cases requiring further consultation between the radiologist and pathologist. There are multiple reasons for misinterpretation of a pathology report. An important and largely underestimated reason is varied interpretations of terms used by the pathologist. Standardized pathology reports with concise phrases as well as multidisciplinary meetings may limit errors and should be encouraged for optimal diagnostic accuracy., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
35. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.
- Author
-
Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, and Asselain B
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms chemistry, Bridged-Ring Compounds administration & dosage, Carbonic Anhydrases genetics, Chemotherapy, Adjuvant, Estrogen Receptor alpha genetics, Female, Humans, Membrane Proteins genetics, Middle Aged, Neoadjuvant Therapy, Oligonucleotide Array Sequence Analysis, Predictive Value of Tests, RNA analysis, Receptors, Estrogen analysis, Taxoids administration & dosage, Treatment Outcome, tau Proteins genetics, Biomarkers, Tumor genetics, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Transcriptome
- Abstract
This study was designed to identify predictive signatures of pathological complete response (pCR) in breast cancer treated by taxane-based regimen, using clinicopathological variables and transcriptomic data (Affymetrix Hgu133 Plus 2.0 devices). The REMAGUS 02 trial (n = 153,training set) and the publicly available M.D. Anderson data set (n = 133, validation set) were used. A re-sampling method was applied. All predictive models were defined using logistic regression and their classification performances were tested through Area Under the Curve (AUC) estimation. A stable set of 42 probesets (31 genes) differentiate pCR or no pCR samples. Single-or 2-probesets signatures, mainly related to ER pathway, were equally predictive of pCR with AUC greater then 0.80. Models including probesets associated with ESR1, MAPT, CA12 or PIGH presented good classification performances. When clinical variables were entered into the model, only CA12 and PIGH, remained informative (p = 0.05 and p = 0.005) showing that a combination of a few genes provided robust and reliable prediction of pCR., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
36. Rare overexpression of anaplastic lymphoma kinase gene in inflammatory and non-inflammatory breast cancer.
- Author
-
Lerebours F, Callens C, Vacher S, Hatem R, Guinebretière JM, and Bièche I
- Subjects
- Anaplastic Lymphoma Kinase, Breast Neoplasms enzymology, Breast Neoplasms pathology, Female, Humans, Inflammatory Breast Neoplasms enzymology, Inflammatory Breast Neoplasms pathology, Reverse Transcriptase Polymerase Chain Reaction, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic, Inflammatory Breast Neoplasms genetics, Receptor Protein-Tyrosine Kinases genetics
- Published
- 2013
- Full Text
- View/download PDF
37. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
- Author
-
Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, and Penault-Llorca F
- Subjects
- Biopsy, Large-Core Needle, Female, Gene Amplification, Humans, Immunohistochemistry, Middle Aged, Predictive Value of Tests, Breast Neoplasms genetics, Genes, erbB-2 genetics, In Situ Hybridization methods, Real-Time Polymerase Chain Reaction methods
- Abstract
Background: Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-embedded core biopsies with "gold standard FISH" for evaluation of HER2 amplification status., Methods: This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183 (22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2 copy number status. The alternative techniques performed on the same cases were commercially available SISH or CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2 (exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy control TSN, LAP3 and ADAMTS16., Results: The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2 copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97% and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773 cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR., Conclusion: These alternative techniques showed an excellent concordance with FISH in core biopsies allowing their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves special attention, as it is reliable, easy to perform and less expensive than ISH tests.
- Published
- 2013
- Full Text
- View/download PDF
38. A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
- Author
-
Weiswald LB, Richon S, Massonnet G, Guinebretière JM, Vacher S, Laurendeau I, Cottu P, Marangoni E, Nemati F, Validire P, Bellet D, Bièche I, and Dangles-Marie V
- Subjects
- Animals, Camptothecin analogs & derivatives, Camptothecin pharmacology, Cell Line, Tumor, Cell Movement physiology, Cell Survival physiology, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Drug Screening Assays, Antitumor, Female, Fluorouracil pharmacology, Humans, Irinotecan, Mice, Mice, Nude, Mice, SCID, Microscopy, Confocal, Neoplasm Transplantation, Random Allocation, Real-Time Polymerase Chain Reaction, Spheroids, Cellular pathology, Transplantation, Heterologous, Xenograft Model Antitumor Assays, Colorectal Neoplasms pathology
- Abstract
Background: Ex vivo colospheres have been previously characterised as a colorectal cancer (CRC) well-rounded multicellular model, exclusively formed by carcinoma cells, and derived from fresh CRC tissue after mechanical dissociation. The ability to form colospheres was correlated with tumour aggressiveness. Their three-dimensional conformation prompted us to further investigate their potential interest as a preclinical cancer tool., Methods: Patient-derived CRC xenografts were used to produce numerous colospheres. Mechanism of formation was elucidated by confocal microscopy. Expression analysis of a panel of 64 selected cancer-related genes by real-time qRT-PCR and hierarchical clustering allowed comparison of colospheres with parent xenografts. In vitro and in vivo assays were performed for migration and chemosensitivity studies., Results: Colospheres, formed by tissue remodelling and compaction, remained viable several weeks in floating conditions, escaping anoikis through their strong cell-cell interactions. Colospheres matched the gene expression profile of the parent xenograft tissue. Colosphere-forming cells migrated in collagen I matrix and metastasised when subrenally implanted in nude mice. Besides, the colosphere responses to 5-fluorouracil and irinotecan, two standard drugs in CRC, reproduced those of the in vivo original xenografts., Conclusion: Colospheres closely mimic biological characteristics of in vivo CRC tumours. Consequently, they would be relevant ex vivo CRC models.
- Published
- 2013
- Full Text
- View/download PDF
39. A case of osteosarcoma in a patient with pycnodysostosis.
- Author
-
Cortisse N, Forget P, Dresse MF, Florkin B, Mascard E, Guinebretière JM, Brugières L, and Hoyoux C
- Subjects
- Adult, Humans, Male, Femoral Neoplasms etiology, Osteosarcoma etiology, Pycnodysostosis complications
- Abstract
Pycnodysostosis is a rare sclerosing bone dystrophy. The main clinical features are short stature and oral and maxillofacial abnormalities such as a large head, a small and underdeveloped face with prominent nose and eyes, irregular dentition, small hands and feet with dystrophic nails, and trunk deformities such as scoliosis. The differential diagnosis is established with other skeletal dysplasias such as osteopetrosis, cleidocranial dysplasia, and idiopathic acro-osteolysis. Since its first description in 1962 by Maroteaux and Lamy, about 100 cases have been published, some of these with uncommon features. We describe the case of a 22-year-old European man with pycnodysostosis who developed a chondroblastic osteosarcoma of the right femur. No case of bone cancer in this sclerosing bone disease had been described so far.
- Published
- 2012
- Full Text
- View/download PDF
40. [Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment)].
- Author
-
Gomez-Brouchet A, Bouvier C, Decouvelaere AV, Larousserie F, Aubert S, Leroy X, Guinebretière JM, Coulomb A, Cassagnau E, de Muret A, Audard V, Marie B, and de Pinieux G
- Subjects
- Biomarkers, Tumor analysis, Biopsy, Bone Neoplasms chemistry, Bone Neoplasms diagnosis, Bone Neoplasms drug therapy, Bone Neoplasms surgery, Combined Modality Therapy, Disease Management, Humans, Interdisciplinary Communication, Magnetic Resonance Imaging, Molecular Targeted Therapy, Osteosarcoma chemistry, Osteosarcoma diagnosis, Osteosarcoma drug therapy, Osteosarcoma surgery, Prognosis, Sarcoma, Ewing chemistry, Sarcoma, Ewing diagnosis, Sarcoma, Ewing drug therapy, Sarcoma, Ewing surgery, Specimen Handling methods, Treatment Outcome, Antineoplastic Agents therapeutic use, Bone Neoplasms pathology, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Osteosarcoma pathology, Pathology, Clinical, Physician's Role, Sarcoma, Ewing pathology
- Abstract
The survival of osteosarcoma and Ewing family tumours has been improved by the introduction of neoadjuvant chemotherapy. The response to preoperative chemotherapy is evaluated on the microscopic analysis of the surgical resection, by the percentage of tumour necrosis according to the Huvos and Rosen's grading. It remains the only reliable prognostic factor for patients and is used to guide the choice of post-operative chemotherapy. The macroscopic and microscopic management of the surgical resection (cf. supra) is essential and is the subject of a specific protocol. Several studies have been conducted to identify news factors able to predict the response to chemotherapy, the tumour aggressiveness and its ability to develop metastases. Inhibitors of mTOR and/or regulators of the balance RANKL/OPG are promising therapeutics. The study's expression of these new factors could be performed on the biopsy and will offer new therapeutic strategy., (Copyright © 2011 Elsevier Masson SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
41. Is there a link between osteofibrous dysplasia and adamantinoma?
- Author
-
Ramanoudjame M, Guinebretière JM, Mascard E, Seringe R, Dimeglio A, and Wicart P
- Subjects
- Adamantinoma etiology, Adamantinoma surgery, Biopsy, Child, Preschool, Diagnosis, Differential, Fibrous Dysplasia of Bone diagnosis, Fibrous Dysplasia of Bone surgery, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Orthopedic Procedures methods, Plastic Surgery Procedures methods, Time Factors, Adamantinoma diagnosis, Fibrous Dysplasia of Bone complications, Tibia
- Abstract
Because of the relative frequency of osteofibrous dysplasia (OFD) and the gravity of adamantinoma, it is important to know whether there is a link between these two entities. A young boy had been followed from the age of 5 years for OFD of the right tibia. At the age of 10, biopsy performed because of pain, revealed OFD-like adamantinoma. Surgery was undertaken, with en bloc proximal tibial resection of 14 cm and reconstruction by free vascularized fibula and internal fixation. This observation illustrates the risk of evolution of OFD-like adamantinoma, showing the same unfavorable evolution as classic adamantinoma. Strict surveillance is mandatory in OFD, with systematic biopsy in case of onset of pain or increased tumor volume., (Copyright © 2011 Elsevier Masson SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
42. Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.
- Author
-
Guillon MA, Mary PM, Brugière L, Marec-Bérard P, Pacquement HD, Schmitt C, Guinebretière JM, and Tabone MD
- Subjects
- Amputation, Surgical, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms mortality, Bone Neoplasms pathology, Child, Preschool, Combined Modality Therapy, Humans, Infant, Kaplan-Meier Estimate, Osteosarcoma mortality, Osteosarcoma pathology, Prognosis, Retrospective Studies, Treatment Outcome, Bone Neoplasms diagnosis, Bone Neoplasms therapy, Osteosarcoma diagnosis, Osteosarcoma therapy
- Abstract
Background: Osteosarcoma is the most common primary bone malignancy in childhood and adolescence. However, it is very rare in children under 5 years of age. Although studies in young children are limited in number, they all underline the high rate of amputation in this population, with conflicting results being recently reported regarding their prognosis., Methods: To enhance knowledge on the clinical characteristics and prognosis of osteosarcoma in young children, we reviewed the medical records and histology of all children diagnosed with osteosarcoma before the age of five years and treated in SFCE (Société Française des Cancers et leucémies de l'Enfant) centers between 1980 and 2007., Results: Fifteen patients from 7 centers were studied. Long bones were involved in 14 cases. Metastases were present at diagnosis in 40% of cases. The histologic type was osteoblastic in 74% of cases. Two patients had a relevant history. One child developed a second malignancy 13 years after osteosarcoma diagnosis.Thirteen children received preoperative chemotherapy including high-dose methotrexate, but only 36% had a good histologic response. Chemotherapy was well tolerated, apart from a case of severe late convulsive encephalopathy in a one-year-old infant. Limb salvage surgery was performed in six cases, with frequent mechanical and infectious complications and variable functional outcomes.Complete remission was obtained in 12 children, six of whom relapsed. With a median follow-up of 5 years, six patients were alive in remission, seven died of their disease (45%), in a broad range of 2 months to 8 years after diagnosis, two were lost to follow-up., Conclusions: Osteosarcoma seems to be more aggressive in children under five years of age, and surgical management remains a challange.
- Published
- 2011
- Full Text
- View/download PDF
43. [Vascular tumors and pseudo-tumors. Well-differentiated angiosarcoma].
- Author
-
Guinebretière JM
- Subjects
- Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Breast Neoplasms surgery, Cell Differentiation, Female, Hemangioma diagnosis, Hemangiosarcoma diagnostic imaging, Hemangiosarcoma pathology, Hemangiosarcoma surgery, Humans, Lymphangioma diagnosis, Mammography, Middle Aged, Prognosis, Risk Factors, Breast Neoplasms diagnosis, Hemangiosarcoma diagnosis
- Published
- 2011
- Full Text
- View/download PDF
44. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.
- Author
-
de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, and Spyratos F
- Subjects
- Antineoplastic Agents therapeutic use, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Chemotherapy, Adjuvant, Cluster Analysis, Female, Humans, Neoadjuvant Therapy, Reproducibility of Results, Research Design, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Reverse Transcriptase Polymerase Chain Reaction
- Abstract
Background: Identification of predictive markers of response to treatment is a major objective in breast cancer. A major problem in clinical sampling is the variability of RNA templates, requiring accurate management of tumour material and subsequent analyses for future translation in clinical practice. Our aim was to establish the feasibility and reliability of high throughput RNA analysis in a prospective trial., Methods: This study was conducted on RNA from initial biopsies, in a prospective trial of neoadjuvant chemotherapy in 327 patients with inoperable breast cancer. Four independent centres included patients and samples. Human U133 GeneChips plus 2.0 arrays for transcriptome analysis and quantitative RT-qPCR of 45 target genes and 6 reference genes were analysed on total RNA., Results: Thirty seven samples were excluded because i) they contained less than 30% malignant cells, or ii) they provided RNA Integrity Number (RIN) of poor quality. Among the 290 remaining cases, taking into account strict quality control criteria initially defined to ensure good quality of sampling, 78% and 82% samples were eligible for transcriptome and RT-qPCR analyses, respectively. For RT-qPCR, efficiency was corrected by using standard curves for each gene and each plate. It was greater than 90% for all genes. Clustering analysis highlighted relevant breast cancer phenotypes for both techniques (ER+, PR+, HER2+, triple negative). Interestingly, clustering on trancriptome data also demonstrated a "centre effect", probably due to the sampling or extraction methods used in on of the centres. Conversely, the calibration of RT-qPCR analysis led to the centre effect withdrawing, allowing multicentre analysis of gene transcripts with high accuracy., Conclusions: Our data showed that strict quality criteria for RNA integrity assessment and well calibrated and standardized RT-qPCR allows multicentre analysis of genes transcripts with high accuracy in the clinical context. More stringent criteria are needed for transcriptome analysis for clinical applications., (© 2011 de Cremoux et al; licensee BioMed Central Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
45. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
- Author
-
Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, and Marty M
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Adult, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms genetics, Breast Neoplasms pathology, Celecoxib, Chemotherapy, Adjuvant, Cyclophosphamide administration & dosage, Disease-Free Survival, Docetaxel, Epirubicin administration & dosage, Female, France, Humans, In Situ Hybridization, Fluorescence, Middle Aged, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Staging, Pyrazoles administration & dosage, Sulfonamides administration & dosage, Taxoids administration & dosage, Therapeutics, Time Factors, Trastuzumab, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Receptor, ErbB-2 genetics
- Abstract
To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addition of celecoxib in HER2 negative patients or trastuzumab in HER2 positive patients. From May 2004 till October 2007, 340 patients with stage II and III breast adenocarcinoma, ineligible for breast conserving surgery, received eight sequential three weekly cycles of EC-D [epirubicin (75 mg/m(2))-cyclophosphamide (750 mg/m(2)) for four cycles followed by docetaxel (100 mg/m(2)) for four cycles]. HER2-negative patients (N = 220) were randomized to receive concomitantly with docetaxel celecoxib 800 mg/day during cycles 5-8 or no additional treatment, while HER2-positive patients confirmed by FISH (N = 120) were randomized to trastuzumab concomitant to docetaxel (8 mg/kg then 6 mg/kg IV every 3 weeks) or no additional preoperative treatment. In the HER2 negative group, pCR (grade 1 and 2 of Chevallier's classification) was observed in 11.5 and 13% of patients treated without and with neoadjuvant Celecoxib, respectively. In the HER2 positive group, pCR rate reached 26% in those who received neoadjuvant trastuzumab versus 19% in the others. There was no unexpected toxicity, no cardiac toxicity, and no toxic death. Triple negative breast cancers experience the highest pCR rate of 30%. Celecoxib is not likely to improve pCR rates in addition to EC-D in patients with HER2-negative tumor. In HER2-positive tumor patients, trastuzumab added to ECD leads to increased pCR rates. It was the only combination to deserve further study according to the two-stage Fleming's design used in this trial.
- Published
- 2010
- Full Text
- View/download PDF
46. In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy.
- Author
-
Weiswald LB, Guinebretière JM, Richon S, Bellet D, Saubaméa B, and Dangles-Marie V
- Subjects
- AC133 Antigen, Antigens, CD biosynthesis, Cell Line, Tumor, Flow Cytometry methods, Gene Expression Profiling, Glycoproteins biosynthesis, Humans, Image Processing, Computer-Assisted methods, Immunohistochemistry methods, Peptides, Gene Expression Regulation, Neoplastic, Microscopy, Confocal methods, Neoplasms pathology, Neoplastic Stem Cells cytology
- Abstract
Background: Multicellular tumour sphere models have been shown to closely mimic phenotype characteristics of in vivo solid tumours, or to allow in vitro propagation of cancer stem cells (CSCs). CSCs are usually characterized by the expression of specific membrane markers using flow cytometry (FC) after enzymatic dissociation. Consequently, the spatial location of positive cells within spheres is not documented. Confocal microscopy is the best technique for the imaging of thick biological specimens after multi-labelling but suffers from poor antibody penetration. Thus, we describe here a new protocol for in situ confocal imaging of protein expression in intact spheroids., Methods: Protein expression in whole spheroids (150 mum in diameter) from two human colon cancer cell lines, HT29 and CT320X6, has been investigated with confocal immunostaining, then compared with profiles obtained through paraffin immunohistochemistry (pIHC) and FC. Target antigens, relevant for colon cancer and with different expression patterns, have been studied., Results: We first demonstrate that our procedure overcomes the well-known problem of antibody penetration in compact structures by performing immunostaining of EpCAM, a membrane protein expressed by all cells within our spheroids. EpCAM expression is detected in all cells, even the deepest ones. Likewise, antibody access is confirmed with CK20 and CD44 immunostaining. Confocal imaging shows that 100% of cells express beta-catenin, mainly present in the plasma membrane with also cytoplasmic and nuclear staining, in agreement with FC and pIHC data. pIHC and confocal imaging show similar CA 19-9 cytoplasmic and membranar expression profile in a cell subpopulation. CA 19-9+ cell count confirms confocal imaging as a highly sensitive method (75%, 62% and 51%, for FC, confocal imaging and pIHC, respectively). Finally, confocal imaging reveals that the weak expression of CD133, a putative colon CSC marker, is restricted to the luminal cell surface of colorectal cancer acini, with CD133+ cellular debris into glandular lumina., Conclusion: The present protocol enables in situ visualization of protein expression in compact three-dimensional models by whole mount confocal imaging, allowing the accurate localization and quantification of cells expressing specific markers. It should prove useful to study rare events like CSCs within tumour spheres.
- Published
- 2010
- Full Text
- View/download PDF
47. [Apocrine lesions in breast pathology].
- Author
-
Suciu V, Menet E, Guinebretière JM, Trassard M, and Vielh P
- Subjects
- Adult, Biopsy, Breast Neoplasms pathology, Female, Fibrocystic Breast Disease pathology, Humans, Metaplasia, Apocrine Glands pathology, Breast pathology
- Published
- 2009
- Full Text
- View/download PDF
48. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.
- Author
-
Rouleau E, Spyratos F, Dieumegard B, Guinebretière JM, Lidereau R, and Bièche I
- Subjects
- Colorectal Neoplasms therapy, Humans, Mutation genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins p21(ras), ras Proteins metabolism, Colorectal Neoplasms enzymology, Colorectal Neoplasms genetics, ErbB Receptors metabolism, Proto-Oncogene Proteins genetics, ras Proteins genetics
- Published
- 2008
- Full Text
- View/download PDF
49. A six-gene signature predicting breast cancer lung metastasis.
- Author
-
Landemaine T, Jackson A, Bellahcène A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretière JM, Ricevuto E, Noguès C, Briffod M, Bièche I, Cherel P, Garcia T, Castronovo V, Teti A, Lidereau R, and Driouch K
- Subjects
- Breast Neoplasms genetics, Cohort Studies, Female, Gene Expression Profiling, Humans, Immunohistochemistry, Lung Neoplasms pathology, Oligonucleotide Array Sequence Analysis, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Breast Neoplasms pathology, Lung Neoplasms secondary, Neoplasm Metastasis
- Abstract
The lungs are a frequent target of metastatic breast cancer cells, but the underlying molecular mechanisms are unclear. All existing data were obtained either using statistical association between gene expression measurements found in primary tumors and clinical outcome, or using experimentally derived signatures from mouse tumor models. Here, we describe a distinct approach that consists of using tissue surgically resected from lung metastatic lesions and comparing their gene expression profiles with those from nonpulmonary sites, all coming from breast cancer patients. We show that the gene expression profiles of organ-specific metastatic lesions can be used to predict lung metastasis in breast cancer. We identified a set of 21 lung metastasis-associated genes. Using a cohort of 72 lymph node-negative breast cancer patients, we developed a 6-gene prognostic classifier that discriminated breast primary cancers with a significantly higher risk of lung metastasis. We then validated the predictive ability of the 6-gene signature in 3 independent cohorts of breast cancers consisting of a total of 721 patients. Finally, we show that the signature improves risk stratification independently of known standard clinical variables and a previously established lung metastasis signature based on an experimental breast cancer metastasis model.
- Published
- 2008
- Full Text
- View/download PDF
50. CXC chemokines located in the 4q21 region are up-regulated in breast cancer.
- Author
-
Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R, and Lazennec G
- Subjects
- Aged, Breast Neoplasms surgery, Cells, Cultured, Chromosome Mapping, Disease-Free Survival, Endothelium, Vascular, Female, Humans, Lymphatic Metastasis, Middle Aged, Reverse Transcriptase Polymerase Chain Reaction, Umbilical Veins, Breast Neoplasms genetics, Breast Neoplasms pathology, Chemokines, CXC genetics, Chromosomes, Human, Pair 4, Gene Expression Regulation, Neoplastic, Up-Regulation
- Abstract
Recent data suggest that chemokines could be essential players in breast carcinogenesis. We previously showed that the CXC chemokine CXCL8 (interleukin-8) was overexpressed in estrogen receptor alpha (ERalpha)-negative breast cell lines. Analysis of CXCL8 chromosomal location showed that several CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL4, CXCL4V1, CXCL5, CXCL6, CXCL7, and CXCL8) were localized in the same narrow region (360 kb in size) of chromosome 4. We thus hypothesized that they could belong to the same cluster. Quantification of these chemokines in breast tumors showed that samples expressing high CXCL8 also produced elevated levels of CXCL1, CXCL3, and CXCL5, and displayed low content of ERalpha. CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 were co-regulated both in tumors and in breast cancer cell lines. CXCL5 and CXCL8 were mainly produced by epithelial cells, whereas CXCL1, CXCL2, and CXCL3 had a high expression in blood cells. The overexpression of these chemokines in tumor cells was not the result of gene amplification, but rather of an enhanced gene transcription. Our data suggest that high CXCL8 expression in tumors is mainly correlated to activating protein-1 (AP-1) pathway and to a minor extent to NF-kappaB pathway. Interestingly, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL8 chemokines were present at higher levels in metastases when compared with grade I and III biopsies. High levels of CXCL8, CXCL1, and CXCL3 accounted for a shorter relapse-free survival of ERalpha-positive patients treated with tamoxifen. In summary, we present evidences that multiple CXC chemokines are co-expressed in CXCL8-positive breast tumors. In addition, these chemokines could account for the higher aggressiveness of these types of tumors.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.